Advertisement

Anesthesiology pp 689-696 | Cite as

Anesthesia for TIPS

  • Ricky Matkins
  • W. Thomas DanielIII
Chapter

Abstract

Transjugular intrahepatic portosystemic shunt (TIPS) is a unique procedure that has been performed for more than 30 years to treat portal hypertension. Today, it is a widely accepted option for patients whose disease is refractory to medical treatment and is a key intervention used to manage both portal hypertension and its associated comorbidities.

This chapter outlines the indications and surgical approach for TIPS, as well as the anesthetic and medical considerations for patients undergoing the procedure. Due to the impact of cirrhosis on the multiple organ systems in the body, extensive clinical considerations are summarized including preoperative evaluation and optimization, intraoperative management and monitoring, and continued post-operative concerns and possible complications.

Keywords

Transjugular Intrahepatic Portosytemic Shunt (TIPS) Portal hypertension Hepatic venous pressure gradient (HPVG) Cirrhosis Varices End-stage liver disease (ESLD) 

References

  1. 1.
    Brunner F, Berzigotti A, Bosch J. Prevention and treatment of variceal haemorrhage in 2017. Liver Int. 2017;37(Suppl. 1):104–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.CrossRefPubMedGoogle Scholar
  3. 3.
    Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38:266–72.CrossRefPubMedGoogle Scholar
  5. 5.
    Boyer T, Haskal Z. American Association for the Study of Liver Diseases Practice Guidelines: the role of transjugular intrahepatic portosystemic shunt creation in the management of portal hypertension. J Vasc Interv Radiol. 2005;16:615–29.CrossRefPubMedGoogle Scholar
  6. 6.
    Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol. 2003;37:703–4.CrossRefGoogle Scholar
  7. 7.
    Sharara A, Rockey D. Gastroesophageal variceal hemorrhage. N Engl J Med. 2001;345:669–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a Multicenter, Cohort Study. Am J Gastroenterol. 2003;98:653–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Runyon B. Management of adult patients with ascites due to cirrhosis. Hepatology. 2004;39:841–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Sanyal A, Genning C, Reddy K, et al., NASTRA group. The North American Study for the treatment of refractory ascites. Gastroenterology. 2003;124:634–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol. 1996;25:135–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Rossle M, Ochs A, Gullberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;342:1701–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Gines P, Uriz J, Calaborra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroeterology. 2002;123:1839–47.CrossRefGoogle Scholar
  14. 14.
    Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized Controlled Study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:629–35.CrossRefGoogle Scholar
  15. 15.
    Brensing K, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosytemic stentshunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000;47:288–95.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wong F, Sniderman K, Liu P, et al. Transjugular stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 1995;122:816–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Guevara M, Gines P, Bandi J, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Scher C. Anesthesia for transjugular intrahepatic portosystemic shunt. Int Anesthesiol Clin. 2009;47:21–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Duranti R, Laffi G, Misuri G, et al. Respiratory mechanics in patients with tense cirrhotic ascites. Eur Respir J. 1997;10:1622–30.CrossRefPubMedGoogle Scholar
  20. 20.
    Monfort P, Cauli O, Montoliu C, et al. Mechanisms of cognitive alterations in hyperammonemia and hepatic encephalopathy: therapeutical implications. Neurochem Int. 2009;55:106–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Schenk P, Fuhrmann V, Madl C, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut. 2002;51:853–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Dalal A. Anesthesia for liver transplantation. Transplant Rev. 2016;30:51–60.CrossRefGoogle Scholar
  23. 23.
    Swanson K, Wiesner R, Nyberg S, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8:2445–53.CrossRefGoogle Scholar
  24. 24.
    Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology. 2006;44:1502–10.CrossRefPubMedGoogle Scholar
  25. 25.
    Krug S, Seyfarth H, Hagendorff A, et al. Inhaled iloprost for hepatopulmonary syndrome: improvements of hypoxemia. Eur J Gastroenterol Hepatol. 2007;19:1140–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Peck-Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Ailment Pharmacol Ther. 2007;26(suppl 1):21–8.CrossRefGoogle Scholar
  27. 27.
    Chana A, James M, Veale P. Anesthesia for transjugular intrahepatic portosystemic shunt insertion. BJA Educ. 2016;16:405–9.CrossRefGoogle Scholar
  28. 28.
    Moreau R, Lebrec D. Acute kidney injury: new concepts. Hepatorenal syndrome: the role of vasopressors. Nephron Physiol. 2008;109:73–9.CrossRefGoogle Scholar
  29. 29.
    Andrea DG, Andrea C, Rocco C, Antonio R, Elena R, Ernestine M, Giuliana F, Manlio P. Transjugular intrahepatic portosystemic shunt (TIPS): the anesthesiological point of view after 150 procedures managed under total intravenous anesthesia. J Clin Monit Comput. 2009;23:341–6.CrossRefGoogle Scholar
  30. 30.
    Roberta H, Katherine M. Stoelting’s Anesthesia and co-existing disease. 2008; p. 259–78.Google Scholar
  31. 31.
    Fun-Sun Y, Robert P, Rae A. Yao and Artusio’s Anesthesiology. 2003; p. 485–509.Google Scholar
  32. 32.
    Thierry G, Francois D, Didier L, Jean-Louis V, Richard M. J Hepatol. 2009;50:2022–33.CrossRefGoogle Scholar
  33. 33.
    Berend M. Should norepinephrine, rather than phenylephrine, be considered the primary vasopressor in anesthetic practice? Anesth Analg. 2016;122:1707–14.CrossRefGoogle Scholar
  34. 34.
    Dennis D, et al. Canadian. J Emerg Med. 2015;17(S1):1–16.Google Scholar
  35. 35.
    Sarkar J, Golden PJ, Kajiura LN, Murata LM, CFT U. Vasopressin decreases pulmonary to systemic vascular resistance ratio in a porcine model of severe hemorrhagic shock. Shock. 2015;43(5):475–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Sun G, Wang J, Teng F, Lu Y, Li Y, Wen A. The effect of acute variceal bleeding interventions on reducing the requirement of blood transfusions in cirrhotic patients: a systematic review. Int J Clin Exp Med. 2016;9(3):6166–77.Google Scholar
  37. 37.
    Rakesh V, Larry MN, Imogen S. Contin Educ Anaesth Crit Care Pain. 2010;10:15–9.CrossRefGoogle Scholar
  38. 38.
    Fagiuoli S, Bruno R, Venon W, Schepis F, Vizzutti F, Toniutto P, Senzolo M, Caraceni P, Salerno F, Angeli P, Cioni R, Vitale A, Grosso M, DeGasperi A, D’Amico G, Marzano A. Consensus Conference on TIPS management: techniques, indications, and contraindications. Dig Liver Dis. 2017;49(2):121–37.CrossRefPubMedGoogle Scholar
  39. 39.
    Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients. J Hepatol. 2012;56(Suppl 1):S13–24.CrossRefPubMedGoogle Scholar
  40. 40.
    Batistaki C, Matsota P, Kalimeris K, Brountzos E, Kostopanagiotou G. Sugammadex antagonizing rocuronium in three patients with liver dysfunction undergoing transjugular intrahepatic portosystemic shunt. Anaesth Intensive Care. 2012;40(3):556–71.PubMedGoogle Scholar
  41. 41.
    Dariushnia S, Haskal Z, Midia M, Martin L, Walker T, Kalva S, Clark T, Ganguli S, Krishnamurthy V, Saiter C, Nikilic B. Quality improvement guidelines for transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2016;27:1–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Jaffe, R. Anesthesiologists manual of surgical procedures. 5th ed. Philadelphia, PA: Wolters Kluwer; 2014. p. 1507–12.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Emory University HospitalEmory University School of MedicineAtlantaUSA

Personalised recommendations